Sharemaestro Newsreel

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

Inogen (INGN) reported a Q2 loss of $0.14 per share, which was better than the Zacks Consensus Estimate of a $0.17 loss, and also surpassed revenue estimates with $95.08 million. Despite underperforming the S&P 500 year-to-date, the company's stock currently holds a Zacks Rank …

AHCO SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AdaptHealth Corp.

SueWallSt, powered by Levi & Korsinsky LLP, has initiated an investigation into AdaptHealth Corp. (NASDAQ: AHCO) after the company significantly lowered its full-year 2026 revenue and adjusted EBITDA guidance, causing a stock drop of up to 26%. The investigation focuses on whether AdaptHealth made …

Profound Medical Reports Second Quarter 2026 Financial Results

Profound Medical Corp. announced strong second-quarter 2026 financial results, with a 16% decline in operating expenses and a 39% improvement in net loss. The company reiterated its full-year 2026 revenue guidance of $25.0 million despite a temporary logistics issue that shifted $3.1 million in …

Earnings Flash (AORT) Artivion, Inc. Posts Q2 Adjusted EPS $0.13 per Share, Vs. FactSet Est of $0.10

Artivion, Inc. (AORT) announced its Q2 adjusted EPS of $0.13 per share, surpassing the FactSet estimate of $0.10. This indicates a stronger financial performance than anticipated by analysts.

STERIS plc (Ireland) Stock 12‑Month Price Target Cut to $260.67, Implies 12% Upside

The average 12-month price target for STERIS plc (Ireland) stock has been lowered from $265.57 to $260.67 by 6 analysts, suggesting a potential 12% upside from its Aug. 5 closing price. Despite the reduction, the consensus rating from 11 analysts remains a "Buy," with …

Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say

GLOBUS MEDICAL ($GMED) Releases Q2 2026 Earnings, Stock Rises

Earnings call transcript: electroCore posts Q2 2026 EPS beat, raises outlook

Enovis Backs 2026 Guidance >ENOV

Enovis is reaffirming its financial guidance for 2026. The company anticipates achieving $2.5 billion in revenue and an adjusted EBITDA margin of 23% by that year. This reiteration suggests confidence in their ongoing business strategies and growth trajectory.

Cytosorbents Crp earnings missed by $0.01, revenue topped estimates

Earnings call transcript: Profound Medical Q2 2026 revenue rises, stock slips 3.5%

Inogen Inc earnings beat by $0.03, revenue topped estimates

Inogen Inc (NASDAQ: INGN) reported its second-quarter earnings, beating analyst EPS estimates by $0.03 with an EPS of $-0.14. The company also surpassed revenue expectations, bringing in $95.1M against a consensus estimate of $95.05M. Despite the beat, the stock has seen a -7.83% decline …

Tandem Diabetes Q2 2026 slides: PayGo model drives margin expansion

Tandem Diabetes Care (NASDAQ:TNDM) reported record Q2 2026 sales of $255 million, despite a slight miss on revenue forecasts, driven by a strategic transition to a "PayGo" pharmacy-based reimbursement model. This new model is expected to more than double lifetime revenue per patient and …

Tandem Diabetes’s (NASDAQ:TNDM) Q2 CY2026 Earnings Results: Revenue In Line With Expectations

Earnings call transcript: Senseonics tops revenue forecasts in Q2 2026

Senseonics Holdings reported a strong Q2 2026, with revenue increasing 120% year-over-year to $14.5 million, exceeding analyst forecasts. Despite a slightly wider-than-expected loss per share of 63 cents, the company raised its full-year 2026 revenue guidance to $62 million-$66 million and achieved its strongest …

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) reported Q2 earnings of $0.13 per share, meeting the Zacks Consensus Estimate, though this is down from $0.24 a year ago. The company's revenues for the quarter were $125.76 million, surpassing estimates by 4.02%. Artivion's stock has underperformed the S&P 500 this …

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA)

This article highlights two healthcare stocks, Insulet (PODD) and Entrada Therapeutics Inc (TRDA), which have received bullish sentiments from analysts. Steven Lichtman of William Blair maintained a Buy rating on Insulet, while Myles Minter, also from William Blair, maintained a Buy rating on Entrada …

Artivion Q2 2026 slides: FDA wins fuel aortic arch expansion

Artivion Inc. reported strong Q2 2026 results, with 9% constant-currency revenue growth driven by stent grafts and On-X mechanical heart valves. The company achieved two major regulatory milestones: FDA PMA approval for the AMDS Hybrid Prosthesis and the completion of the Endospan acquisition following …

Outset Medical (OM) Stock Falls on Q2 2026 Earnings

Outset Medical (OM) reported Q2 2026 revenue of $31.6 million, exceeding analyst expectations, but its stock fell 3.4% after market close due to a widened operating loss and a larger-than-estimated net loss per share. Insider activity shows significant selling, while institutional investors present a …

Earnings call transcript: Outset Medical posts mixed Q2 2026 results, shares edge up

Outset Medical reported mixed Q2 2026 results, with revenue slightly exceeding expectations at $31.6 million but an adjusted loss per share of $0.80, wider than the anticipated $0.75. Shares saw a modest increase of 0.96% in after-hours trading. The company reiterated its full-year 2026 …

Earnings call transcript: STERIS beats Q1 2026 EPS, shares fall on spending plans

STERIS plc reported Q1 2027 earnings that beat analyst estimates but saw its shares fall due to investor concerns over increased capital spending plans, including a new $600 million manufacturing facility in North Carolina, and softer near-term segment trends. Despite the earnings beat and …

Apyx Medical Corporation (APYX) Stock Falls on Q2 2026 Earnings

(IRTC) IRhythm Technologies Expects 2026 Revenue Range $880M - $890M, vs. FactSet Est of $881.1M

iRhythm Technologies (IRTC) has announced its revenue expectations for 2026, forecasting a range of $880 million to $890 million. This projection is in line with FactSet's estimated revenue of $881.1 million for the same period. The company also reported its Q2 2026 earnings, with …

iRhythm Holdings, Inc. Quarterly Earnings Report

QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates

QuidelOrtho (QDEL) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

iRhythm (NASDAQ:IRTC) Beats Q2 CY2026 Sales Expectations

iRhythm (NASDAQ:IRTC) Beats Q2 CY2026 Sales Expectations Medical technology company iRhythm Technologies (NASDAQ:IRTC) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 20.1% year on year to $224.2 million. The company expects the full year's revenue to be around $885 million, close …

[10-Q] Outset Medical, Inc. Quarterly Earnings Report

UFP Technologies Q2 2026: Revenue $173.96M, EPS $2.68— 10-Q Summary

UFP Technologies reported strong second-quarter 2026 results with revenue of $173.96 million and diluted EPS of $2.68, showing significant year-over-year growth. The company's financial performance was driven by a 15.1% YoY increase in revenue and a 21.3% YoY rise in net income and EPS, …

UFP Technologies (NASDAQ: UFPT) grows Q2 2026 sales and earnings

UFP Technologies reported strong financial results for Q2 2026, with net sales increasing by 15.1% to $174.0 million and diluted EPS reaching $2.68. The growth was primarily driven by its medical sub-markets, leading to an improved gross margin of 29.3%. Despite these gains, the …

Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q2 Revenue $630.9M, vs. FactSet Est of $618.7M

QuidelOrtho Corporation (QDEL) reported its Q2 revenue at $630.9 million, surpassing FactSet's estimate of $618.7 million. This announcement indicates stronger-than-expected financial performance for the company in the second quarter. The article also mentions recent changes in the company's indices and the appointment of a …

QT Imaging Holdings (QTI) director Timm Bryan files Form 3 showing no holdings

QT Imaging Holdings, Inc. director Timm Bryan has filed an initial Form 3, an SEC statement of beneficial ownership. The filing indicates no insider transactions, derivative positions, or reportable holdings in the company's securities for Bryan at the time of disclosure. This Form 3 …

TriSalus Life Sciences, Inc. 2026: Revenue $11.41M, EPS ($0.16) — 10-Q Summary

TriSalus Life Sciences, Inc. (TLSI) reported its 2026 quarterly results, showing revenue of $11.41M, which was nearly flat year-over-year, and a net loss of ($9.19M), resulting in a diluted loss per share of ($0.16). The company highlighted stable revenue, improved gross margin, continued commercial …

Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside

The average 12-month price target for Sight Sciences, Inc. (SGHT) stock has been raised from $8.4 to $8.6 by 5 analysts, with a range of $6 to $12 per share. This new target suggests a potential upside of approximately 55% based on the August …

Segall Bryant & Hamill LLC Acquires New Holdings in Tactile Systems Technology, Inc. $TCMD

Segall Bryant & Hamill LLC has acquired 49,382 shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD) worth approximately $1.29 million, indicating growing institutional interest in the company. Other institutional investors have also increased their stakes in TCMD, with 83.43% of the stock now owned by …

Janus Henderson Group PLC Purchases 127,942 Shares of Tactile Systems Technology, Inc. $TCMD

Janus Henderson Group PLC increased its stake in Tactile Systems Technology, Inc. (TCMD) by 67.4% in the first quarter, acquiring an additional 127,942 shares to bring its total holdings to 317,695 shares valued at $8.3 million. Institutional investors now own 83.43% of the company, …